Table 1 Tumors associated with m6A methylation.

From: Progression of m6A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming

Tumor type

m6A regulator

Mechanism and effect

References

HNSCC

ALKBH5

Inhibiting ALKBH5/RIG-I/IFNα axis and promoting tumor development

[142]

NPC

FTO

Suppressing immune cell levels and reducing survival

[177]

OSCC

FTO

Increasing expression of PD-L1 transcripts and promoting tumor development

[279]

GBM

METTL3

Promoting maturation of SLC7A11 mRNA and suppressing ferroptosis

[280]

 

ALKBH5

Promoting expression level of FOXM1 and promoting tumor proliferation and metastasis

[281]

EC

FTO

Promoting expression of HSD17B11 and facilitating tumor progression

[103]

BC

METTL3/ IGF2BP3

Stabilizing PD-L1 mRNA via METTL3/IGF2BP3 axis and promoting tumor immune escape

[137]

 

YTHDF1

Inhibiting PKM2 expression and promoting tumor growth and metastasis

[85]

 

YTHDF3

Enhancing expression of m6A-enriched gene transcripts and facilitating malignancy

[282]

 

WTAP

Increasing ENO1 mRNA stability and promoting tumor development

[283]

LC

METTL3

Reducing gene expression of HMBOX1 and promoting tumor proliferation

[284]

 

METTL3/ ALKBH5

Enhancing ENO1 translation and promoting tumorigenesis

[285]

 

YTHDF2

Activating mTOR/AKT and promoting tumorigenesis and invasion

[68]

 

YTHDC2

Inhibiting SLC3A2 expression via YTHDC2/HOXA13/SLC3A2 axis and inducing ferroptosis

[286]

 

FTO

Inhibiting Wnt/β-catenin/FTO/c-Myc and suppressing tumor progression

[287]

 

IGF2BP1

Inhibiting Netrin-1 expression and suppressing tumor progression

[288]

HCC

METTL3

Stabilizing lncRNA LINC00958 and facilitating tumor development

[96]

 

METTL14

Increasing MIR155HG stability through METTL14/MIR155HG/PD-L1 axis and promoting tumor immune escape

 
 

YTHDF1/ METTL3

Enhancing EMT by mediating Snail mRNA translation and promoting tumor metastasis

[289]

 

YTHDF2

Inhibiting IL-11 and SERPINE2 RNA degradation and inducing tumorigenesis

[290]

 

WTAP

Blocking cell cycle transition and facilitating tumor progression

[291]

GC

METTL3

Accelerating m6A methylation of HDGF mRNA and promoting tumor development

[292]

 

METTL14

Suppressing LHPP expression and promoting tumor progression

[293]

 

WATP

Promoting HK2 mRNA stability and facilitating tumor progression

[90]

PC

ALKBH5

Aggregating CD8+ and CD4+ T cells and promoting tumor evade immune surveillance

[294]

PDAC

YTHDF3

Promoting miR-30d and inhibiting RUNX1 via YTHDC1/miR-30d/RUNX1axis and inhibiting tumorigenesis

[88]

CRC

METTL3

Enhancing the stability of HK2 and GLUT1 transcripts and facilitating tumor progression

[224]

 

METTL14

Affecting normal function of CD8+ T cells and facilitating malignancy

[295]

 

YTHDF1

Enhancing cisplatin resistance through metabolic reprogramming and suppressing tumor cell death

[114]

 

IGF2BP2

Increasing MYC mRNA stability via the LINRIS-IGF2BP2-MYC axis and promoting tumor development

[235]

 

FTO

Reducing MTA1 mRNA stability and suppressing tumor progression and metastasis

[73]

BCa

METTL3

Stabilizing PD-L1 mRNA via JNK/METTL3/PD-L1 axis and promoting tumor immune escape

[296]

 

ALKBH5

Inhibiting stability of CK2α mRNA and inhibiting cisplatin resistance

[297]

RCC

METTL14

Inhibiting BPTF mRNA stability and suppressing tumor metastasis

[298]

 

IGF2BP1

Stabilizing mRNA and promoting G1/S cell cycle transition and enhancing tumor growth

[299]

 

FTO

Inhibiting YTHDF2-dependent Unc-51-like kinase 1 mRNA decay and promoting tumor development

[300]

ccRCC

FTO

Increasing expression of SLC1A5 and facilitating tumor progression

[115]

OC

METTL3

Promoting maturation and function of NK cells and improving immune function

[170]

 

ALKBH5

Increasing EGFR-PIK3CA-AKT-mTOR activity and promoting tumor progression

[301]

CC

METTL3/ YTHDF1

Stabilizing HK2 mRNA through YTHDF1 and promoting tumor development

[86]

PCa

YTHDF2

Binding to NKX3-1 and LHPP and facilitating tumor growth

[302]

Leukemia

METTL3

Affecting epithelial-mesenchymal transition in cancer cells by altering TGFβ1 expression and secretion and promoting tumor progression

[303]

 

YTHDF2

Inhibiting m6A expression via AML1/ETO-HIF-1α-YTHDF2 axis and accelerating tumor growth

[304]

Melanoma

FTO

Inhibiting CD8+ T cells function by promoting expression of transcription factors c-Jun, JunB, and C/EBPβ and facilitating immune evasion

[92]

 

YTHDF2

Promoting maturation and function of NK cells and improving immune function

[169]

  1. m6A N6-methyladenosine, HNSCC head and neck squamous cell carcinoma, NPC nasopharyngeal carcinoma, OSCC oral squamous cell carcinoma, GBM glioblastoma, EC esophageal cancer, BC breast cancer, LC lung cancer, HCC hepatocellular carcinoma, GC gastric cancer, PC pancreatic cancer, PDAC pancreatic ductal adenocarcinoma, CRC colorectal cancer, BCa bladder cancer, RCC renal carcinoma, ccRCC renal clear cell carcinoma, OC ovarian Cancer, CC cervical cancer, PCa prostatic carcinoma.
Back to article page